Sanofi's Matthew Ros Joins Epizyme
Epizyme Inc. has appointed Matthew Ros chief operating officer (COO). Ros joins the clinical-stage biopharma company from Sanofi, where he was most recently COO, global head of the oncology business unit, overseeing its solid tumour and hematology franchise. Prior to this, he worked within Genzyme’s rare disease business, where he led its second-largest franchise, Pompe disease, as vice president and franchise head. He has also previously served on the board of trustees at CancerCARE.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.